TrivarX (ASX:TRI) secured firm commitments to raise nearly AU$2.3 million through the placement of 150 million new fully paid ordinary shares at AU$0.015 apiece, according to a Monday filing with the Australian bourse.
The issue price is a nearly 10% discount to the company's 15-day volume-weighted average price.
Participants will be issued one free attaching option for every two new shares subscribed for with an exercise price of AU$0.025 and expiring two and a half years from the date of issue, per the filing.
Proceeds will fund the upcoming clinical trial with the US Department of Veterans Affairs and other ongoing research and development initiatives, the filing stated.
TrivarX's shares climbed nearly 7% in recent Monday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。